The Philips CPAP lawsuit has entered a critical new phase in 2026. Settlement checks are actively flowing to tens of thousands of claimants under the $1.1 billion personal injury agreement — but 624 cancer and serious-injury cases remain unresolved in federal court, no court-approved individual cancer injury settlements have been issued, and a second Class I FDA recall issued in August 2024 has opened the door for an entirely new wave of potential claimants. If you used a recalled Philips CPAP, BiPAP, or ventilator device and have not yet determined where you stand legally, this update is urgent reading.
Where the Philips CPAP Lawsuit Stands Right Now in 2026
The Philips CPAP lawsuit traces its origins to June 2021, when Philips Respironics recalled approximately 5.5 million CPAP, BiPAP, and mechanical ventilator devices in the United States — roughly 15 million units worldwide. The recall was triggered by the degradation of polyester-based polyurethane (PE-PUR) sound-abatement foam embedded in the devices. As that foam breaks down, it releases toxic black particles and carcinogenic gases directly into the breathing pathways of patients. The chemicals at issue — toluene diamine, toluene diisocyanate, and diethylene glycol — are classified as potential or known carcinogens. The FDA designated the recall as Class I, its most serious category, reserved for situations where there is a reasonable probability that use of the product will cause serious injury or death.
All litigation was consolidated into MDL 3014 in the Western District of Pennsylvania under Senior Judge Joy Flowers Conti. As of September 2026, there are 624 pending cases in MDL 3014, with zero court-approved individual cancer injury settlement offers having been issued. That number is the single most important data point for anyone following this mass tort in 2026: the economic-loss and medical monitoring tracks are in disbursement, but cancer claimants are still waiting — and actively litigating. An April 21, 2026 scheduling order has set general-causation expert work through July 30, with evidentiary briefing running from August 27 through October 15, 2026, signaling that the court is pressing this litigation toward resolution.
The Two Settlement Tracks: What Has Been Paid and What Has Not
Understanding the Philips CPAP lawsuit settlement landscape requires separating two distinct compensation frameworks that were negotiated years apart and cover fundamentally different categories of harm.
The $479 Million Economic-Loss Class Action Settlement (September 2023)
In September 2023, Philips settled an economic-loss class action for $479 million. This settlement addressed device replacement costs and diminished value damages — it compensated users for the economic harm of owning a defective device. Critically, this settlement does not compensate anyone for personal physical injuries, cancers, or death. It was a property and consumer-harm settlement, not a medical injury settlement. Economic loss claimants are receiving payouts in the range of $100 to $1,500 per person, depending on the nature and documentation of their claim. Many device owners who registered for this track have already received payment.
The $1.1 Billion Personal Injury and Wrongful Death Settlement (April/May 2024)
In April and May of 2024, Philips reached a broader $1.1 billion personal injury and wrongful death settlement — the agreement that affects claimants who developed diagnosed medical conditions they attribute to foam degradation exposure. This settlement covers a wide range of injuries, from respiratory conditions and organ damage to diagnosed cancers. Personal injury claimants with diagnosed conditions face awards expected to reach $50,000 or higher for severe cancers or organ damage, with the exact amount determined by injury tier, duration of device use, and supporting medical documentation. Settlement checks began flowing to eligible claimants following court approval and the registration and claims administration process that followed.
What Remains Unresolved: The 624 Live Cancer Cases
Despite the headline $1.1 billion figure, not every cancer claimant accepted — or was included in — the personal injury settlement. As of September 2026, 624 cases remain pending in MDL 3014, and no court-approved individual cancer injury settlement offers have been issued for these claimants. These are plaintiffs who either opted out of the broader settlement, whose claims were not resolved under its terms, or who filed after the settlement’s registration window closed. For these individuals, litigation is active and ongoing. The April 2026 scheduling order governing general-causation expert deadlines and evidentiary briefing through October 15, 2026 reflects a litigation track that is moving — but has not yet produced resolution for this remaining group.
Key Statistics: Philips CPAP Recall and Lawsuit Data Table
| Data Point | Figure |
|---|---|
| U.S. devices recalled (2021) | ~5.5 million |
| Worldwide devices recalled | ~15 million |
| MDL docket | MDL 3014, W.D. Pennsylvania |
| Pending MDL cases (September 2026) | 624 |
| Court-approved individual cancer settlements | None |
| Economic-loss settlement value | $479 million |
| Economic-loss payout range per person | $100–$1,500 |
| Personal injury settlement value | $1.1 billion |
| Severe cancer/organ damage award range | $50,000+ |
| Second Class I recall issued | August 4, 2024 |
| Devices in second recall | Philips BiPAP A30, A40, and V30 ventilators |
| Deaths linked to second recall | At least 8 |
| General-causation expert deadline (MDL) | July 30, 2026 |
| Evidentiary briefing window (MDL) | August 27 – October 15, 2026 |
The August 2024 Second Class I Recall: A New Category of Claimants
While much of the legal attention in 2026 remains focused on the original 2021 foam-degradation recall, a second and entirely separate Class I recall issued on August 4, 2024 has created a new category of potential claimants that many observers have not yet fully absorbed. The FDA issued this recall covering Philips BiPAP A30, A40, and V30 ventilators after identifying a critical Ventilator Inoperative alarm failure. Unlike the foam-degradation defect, this issue involves the device’s failure to alert users and caregivers when the ventilator stops functioning — a failure with potentially immediate and fatal consequences for patients who depend on mechanical ventilation to breathe.
The FDA linked the alarm failure to at least eight deaths and 13 injuries at the time the recall was issued. Because this recall involves a different defect, a different device category, and a different mechanism of harm than the original 2021 recall, it is not covered by the existing $479 million or $1.1 billion settlements. Individuals or families who were harmed by a Ventilator Inoperative alarm failure on an affected BiPAP A30, A40, or V30 device should treat this as a legally distinct claim that requires separate evaluation. As of 2026, litigation arising from the August 2024 recall is in its early stages, and no consolidated MDL or global settlement specific to this defect has been announced.
What Philips Knew and When: The Internal Discovery Timeline
One of the most damaging aspects of the Philips CPAP litigation has been the internal document record unearthed during discovery. Court filings and investigative reporting have established that Philips Respironics received complaints about foam degradation and potential off-gassing years before the June 2021 recall. Internal communications indicate awareness of the PE-PUR foam problem as early as 2015 and 2016. Regulatory submissions and engineering records suggest that the company understood the potential for foam breakdown under heat and humidity conditions — precisely the conditions that exist inside a CPAP machine in routine use.
Despite this internal knowledge, Philips continued selling affected devices, continued marketing them as safe and effective, and did not initiate a recall or issue a public safety warning for years. When the recall finally came in 2021, it affected devices that had been on the market — and in patients’ bedrooms — for more than a decade. Plaintiffs’ attorneys have used this timeline aggressively in litigation, arguing that Philips’s delay in acting constitutes not just negligence but conscious disregard for patient safety. This discovery record has been central to the litigation strategy for claimants still pursuing individual cancer injury claims through the MDL in 2026.
Are You Still Eligible? Who Can File a Claim in 2026
Eligibility in 2026 depends heavily on which category of harm applies to your situation and which settlement track — if any — you have already participated in.
If you registered and received payment under the $479 million economic-loss settlement, your property and device-value claims are resolved. However, accepting that settlement does not bar you from pursuing a separate personal injury claim if you have a diagnosed medical condition linked to device use — the two tracks were designed to be independent.
If you registered under the $1.1 billion personal injury settlement and your claim is being processed, you are in the disbursement phase. The timeline for individual payments varies based on injury tier, documentation completeness, and claims administration backlog. Claimants with higher-tier injuries — particularly diagnosed cancers and severe organ damage — should expect awards of $50,000 or more, though exact amounts depend on individual claim details.
If you have a diagnosed cancer or serious injury and did not register before the settlement deadline, your situation is more complex. Some late claimants may have options through the ongoing MDL litigation, depending on the nature of their claim, their state’s applicable statute of limitations, and whether a tolling agreement or other mechanism preserved their right to sue. This is precisely the scenario that requires immediate consultation with a mass tort attorney, because procedural deadlines in mass litigation are typically unforgiving.
If you were harmed by a Philips BiPAP A30, A40, or V30 ventilator due to the Ventilator Inoperative alarm failure identified in the August 2024 recall, you are likely pursuing an entirely new and separate legal claim. The existing settlements do not cover this device defect, and litigation related to the 2024 recall is developing independently in 2026.
If you used a recalled device but have no diagnosed injury, medical monitoring claims were part of earlier settlement discussions, but the availability of that remedy depends on the specific terms of the settlement track applicable to your situation. Documentation of device use — model number, serial number, purchase records, prescription records — remains important to preserve regardless of current claim status.
Frequently Asked Questions About the Philips CPAP Lawsuit in 2026
FAQ 1: Is the Philips CPAP lawsuit settlement still paying out in 2026?
Yes, for the tracks that have been resolved. The $479 million economic-loss settlement is in active disbursement, with claimants receiving payments in the range of $100 to $1,500 per person. The $1.1 billion personal injury settlement is also in the payment phase for eligible registered claimants. However, the 624 cases still pending in MDL 3014 involve cancer and serious-injury plaintiffs who have not received court-approved settlement offers and remain in active litigation as of September 2026.
FAQ 2: What cancers are linked to Philips CPAP foam exposure?
The PE-PUR foam degradation releases chemicals including toluene diamine, toluene diisocyanate, and diethylene glycol — compounds associated with a range of cancers and organ injuries. Cancers frequently cited in litigation include kidney cancer, liver cancer, bladder cancer, thyroid cancer, and certain respiratory tract cancers. Plaintiffs have also alleged non-cancer injuries including liver damage, kidney damage, and respiratory conditions. The general-causation expert process underway in the MDL through July 2026 is directly focused on establishing the scientific basis for linking these chemical exposures to specific diagnosed conditions.
FAQ 3: What is the August 2024 second Philips recall and who does it affect?
On August 4, 2024, the FDA issued a Class I recall of Philips BiPAP A30, A40, and V30 ventilators due to a Ventilator Inoperative alarm failure — a defect that caused the devices to fail to alert users when the ventilator stopped working. The FDA connected this failure to at least eight deaths and 13 injuries. This recall is legally and factually separate from the original 2021 foam-degradation recall. It is not covered by the existing MDL settlements. Patients, families, and caregivers who experienced harm related to an alarm failure on one of these specific devices should seek independent legal counsel to evaluate a claim that is distinct from the foam-exposure litigation.
FAQ 4: I missed the January 2025 settlement registration deadline. Do I have any legal options?
Potentially, yes — but the options are narrow and time-sensitive. Missing the settlement registration deadline does not automatically extinguish a legal claim, but it does remove the most straightforward path to compensation. Depending on your state, the statute of limitations for a personal injury claim based on CPAP foam exposure may still be open, particularly if your diagnosis is recent or if you were not reasonably aware of the connection between your device and your illness until recently. The 624 cases still active in MDL 3014 as of September 2026 represent claimants who are pursuing exactly this kind of outside-settlement resolution. Consulting a mass tort attorney quickly is essential, because statutes of limitations vary by state and can close without warning.
FAQ 5: How much is a Philips CPAP personal injury claim worth?
Claim values vary significantly based on injury severity, duration of device use, medical documentation, and which compensation track applies. Under the $479 million economic-loss settlement, payouts are running in the range of $100 to $1,500 per claimant. Under the $1.1 billion personal injury settlement, claimants with severe cancers or significant organ damage can expect awards of $50,000 or higher, with exact figures determined by injury tier and supporting documentation. For the 624 cases still in MDL litigation as of September 2026, no settlement values have been court-approved, meaning those claimants’ ultimate recovery — whether through a future negotiated settlement or trial — remains undetermined. Higher-tier cancer diagnoses with strong causation evidence and extended device use history have historically carried the highest valuations in comparable mass tort litigation.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.